This Article Full Text Full Text (PDF) All Versions of this Article: 117/3/411    most recent CIRCULATIONAHA.107.707380v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morony, S. Articles by Demer, L. L. Search for Related Content PubMed PubMed Citation Articles by Morony, S. Articles by Demer, L. L. Related Collections Animal models of human disease Pathophysiology Other arteriosclerosis Other Vascular biology Related Article

(Circulation. 2008;117:411-420.)
© 2008 American Heart Association, Inc.

Vascular Medicine

Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr^(–/–) Mice

Sean Morony, PhD; Yin Tintut, PhD; Zina Zhang, BS; Russell C. Cattley, VMD, PhD; Gwyneth Van, BA; Denise Dwyer, BS; Marina Stolina, PhD; Paul J. Kostenuik, PhD; Linda L. Demer, MD, PhD

From the Departments of Molecular Cellular and Integrative Physiology (S.M.), Medicine (Y.T., Z.Z., L.L.D.), and Physiology (L.L.D.), University of California, Los Angeles, and Departments of Pathology (R.C.C., G.V.) and Metabolic Disorders (S.M., D.D., M.S., P.J.K.), Amgen Inc, Thousand Oaks, Calif.

Correspondence to Linda L. Demer, MD, PhD, Department of Medicine, David Geffen School of Medicine at UCLA, Box 951679, 10833 LeConte Ave, Los Angeles, CA 90095–1679. E-mail ldemer{at}mednet.ucla.edu

Received April 5, 2007; accepted October 22, 2007.

Background— The role of osteoprotegerin in vascular disease is unclear. Recent observational studies show that serum osteoprotegerin levels are associated with the severity and progression of coronary artery disease, atherosclerosis, and vascular calcification in patients. However, genetic and treatment studies in mice suggest that osteoprotegerin may protect against vascular calcification.

Methods and Results— To test whether osteoprotegerin induces or prevents vascular disease, we treated atherogenic diet–fed ldlr^(–/–) mice with recombinant osteoprotegerin (Fc-OPG) or vehicle for 5 months. Vehicle-treated mice developed significant, progressive atherosclerosis with increased plasma osteoprotegerin levels, consistent with observational studies, and 15% of these atherosclerotic lesions developed calcified cartilage-like metaplasia. Treatment with Fc-OPG significantly reduced the calcified lesion area without affecting atherosclerotic lesion size or number, vascular cytokines, or plasma cholesterol levels. Treatment also significantly reduced tissue levels of aortic osteocalcin, a marker of mineralization.

Conclusions— These data support a role for osteoprotegerin in the vasculature as an inhibitor of calcification and a marker, rather than a mediator, of atherosclerosis.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 117: 331-332. [Extract] [Full Text]

This article has been cited by other articles:

				M. Mizobuchi, D. Towler, and E. Slatopolsky Vascular Calcification: The Killer of Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1453 - 1464. [Abstract] [Full Text] [PDF]

				R. Westenfeld, C. Schafer, T. Kruger, C. Haarmann, L. J. Schurgers, C. Reutelingsperger, O. Ivanovski, T. Drueke, Z. A. Massy, M. Ketteler, et al. Fetuin-A Protects against Atherosclerotic Calcification in CKD J. Am. Soc. Nephrol., June 1, 2009; 20(6): 1264 - 1274. [Abstract] [Full Text] [PDF]

				S. Panizo, A. Cardus, M. Encinas, E. Parisi, P. Valcheva, S. Lopez-Ongil, B. Coll, E. Fernandez, and J. M. Valdivielso RANKL Increases Vascular Smooth Muscle Cell Calcification Through a RANK-BMP4-Dependent Pathway Circ. Res., May 8, 2009; 104(9): 1041 - 1048. [Abstract] [Full Text] [PDF]

				E. Adiguzel, P. J Ahmad, C. Franco, and M. P Bendeck Collagens in the progression and complications of atherosclerosis Vascular Medicine, February 1, 2009; 14(1): 73 - 89. [Abstract] [PDF]

				G. Rashid, E. Plotkin, O. Klein, J. Green, J. Bernheim, and S. Benchetrit Parathyroid hormone decreases endothelial osteoprotegerin secretion: role of protein kinase A and C Am J Physiol Renal Physiol, January 1, 2009; 296(1): F60 - F66. [Abstract] [Full Text] [PDF]

				P. Secchiero and G. Zauli Letter by Secchiero and Zauli Regarding Article, "Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr(-/-) Mice" Circulation, July 8, 2008; 118(2): e18 - e18. [Full Text] [PDF]

				S. Morony, D. Dwyer, M. Stolina, P. J. Kostenuik, Y. Tintut, Z. Zhang, L. L. Demer, R. C. Cattley, and G. Van Response to Letter Regarding Article, "Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr(-/-) Mice" Circulation, July 8, 2008; 118(2): e19 - e19. [Full Text] [PDF]

				L. L. Demer and Y. Tintut Vascular Calcification: Pathobiology of a Multifaceted Disease Circulation, June 3, 2008; 117(22): 2938 - 2948. [Full Text] [PDF]

				L. N. Bakhireva, G. A. Laughlin, R. Bettencourt, and E. Barrett-Connor Does Osteoprotegerin or Receptor Activator of Nuclear Factor-{kappa}B Ligand Mediate the Association between Bone and Coronary Artery Calcification? J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 2009 - 2012. [Abstract] [Full Text] [PDF]

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]